Niki BioSolutions, Inc. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
Niki BioSolutions, Inc. (NIKI) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $1.00 million for the 12-month period ending 2024-12-31, per its S-4/A filed 2026-05-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2026-05-11
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month |
|---|---|
| 2024-12-31 | $1.00M S-4/A · filed 2026-05-11 |